*Together with

?See Today’s Top Biotech Stock Idea!?

Good morning, 360 –

Here are our top trading ideas today – these setups look primed! And don’t forget to check out our TOP headlines (lots today). Be the best prepared trader on the Street!

LGMK – Up over 50% in pre-market after strong earnings surprise

BMEA – 2nd day play. Closed up over 99% yesterday on positive data for its Type-2 diabetes drug

LULU – Up over 16% in pre-market after better than expected earnings and guidance

*A message from Market News Reporting

? Hot Stock of the Day ?

We don’t like to brag often, but you gotta give the “360 team” some props!

On Monday, we highlighted a tiny gold stock you probably never heard of, but was oozing with potential.

Well, we hope you were paying attention…

Today, we are revisiting another recent top performer that has taken a breather after hitting a 52-week high earlier this month.

It is a no-brainer to take a look at the stock at these levels now.

It is a small biotech stock that is currently in a “Phase III” study, checks all of the boxes when looking at technical indicators, and SeekingAlpha reports that the analysts who cover it have an average rating more than 260% higher than the current price!

Do yourself a favor and check out all the juicy details right now. At this price, who knows how long it will last?

Take a minute and read the report our friends at Market News Reporting have put together on this exciting idea… you won’t regret it!

LGMK – Up over 50% in pre-market after strong earnings surprise

Logicmark (LGMK) announced strong revenue and margin growth for the year ended 2022. Revenue for the year was $11.9 million, up 19% year over year. Gross profit was $7.2 million vs $5.8 million the year prior, a 25% increase. Gross profit increased as a result of higher revenues and lower inbound freight costs. Gross margin increase to 60.7% vs 57.7%.

The company’s cash balance on December 31, 202 was $7million.

According to Finviz, LGMK’s market cap was only $3.07 at yesterday’s close, meaning the company’s cash balance is more than 100% higher than the company’s market cap at yesterday’s close. The stock is also down over 90% over the last 12 months.

The stock is gapping 50% higher post the news.

$0.22 has been a resistance area in the pre-market and should be an important pivot point today.

Above it, the first target for bulls would be the pre-market high at $0.2350. Beyond that targets to the upside are $0.25, $0.3 and a gap to fill at $0.3652.

Below $0.22, there is potential support at $0.1950, $0.18, $0.16 and a gap to fill at $0.1401.

BMEA – 2nd day play. Closed up over 99% yesterday on positive data for its Type-2 diabetes drug

Biomea Fusion (BMEA) announced that its Type-2 diabetes drug BMF-219 achieved positive Phase 2 data in its 219 person study. According to the Phase 2 study, 89% of patients achieved a reduction in A1c, 78% of patients achieved at least a 0.5% reductions in A1c, and 56% achieved at least a 1% reduction in A1c.

Investors cheered the results as BMEA rocketed to all-time highs and closed the day up over 99%.

Citigroup raised its price target on the stock to $60, and Piper Sandler raised its to $40. BMEA closed the day at $30.71.

The company also announced this morning that it would be raising $125 million through a public offering of common stock.

Yesterday’s high was $31.54 and that should be a major level to watch today. Above it are all-time highs, and there is only blue sky above.

Yesterday, BMEA had a $10 range from low to high, so that is something to take into account today. Potential targets above are round numbers such as $35, etc.

Below $31.54, there is potential support at $29.50, $26.50, $24.20 and $21.80.

LULU – Up over 16% in pre-market after better than expected earnings and guidance

Lululemon Athletica (LULU) reported Q4 EPS of $4.40 vs $4.26 expected. Revenue came in at $2.8 billion vs $2.7 billion expected.

The company issued guidance seeing Q1 2024 EPS of $1.93-$2.00 vs $1.64 consensus. LULU also sees full year 2024 EPS of $11.50-$11.72 vs $11.26 consensus.

Investors loved the earnings beat and better than expected guidance (full year guidance is usually most important) and the stock is trading 16% higher in the pre-market on the news.

The pre-market high of $374.69 will be the first major target for bulls.

Above it, targets to the upside are $377.20, $380, $384 and $386.70 with $390 and $400 above that.

Below $374.69 there is potential support at $366.50, $360, $350 and $340 below that.

Economic Calendar (EST)

7:00am MBA Mortgage applications

10:00am Fed Speaker Michael Barr

10:00am Pending home sales index

10:00am State Street investor Confidence index

10:30am EIA Petroleum status report

Earnings for Today (After Market)

ASNS, AXDX, BCDA, BCEL, BEEM, CNXC, CXM, DERM, DFLI, DYAI, FC, FUL, KBNT, LTBR, MRAI, OCX, OPGN, PEV, PL, REED, RH, SMTC, SNAL, VIEW, VRNT, WAVE, XOS

Top Headlines

ELV: The Standard to Acquire Life & Disability Business from Elevance Health; Companies Announce Future Distribution Partnership

OPRT: Oportun Informed by Consumer Financial Protection Bureau that it has Concluded its Investigation of Oportun and Will Not Recommend any Enforcement Action

MNTK: Montauk Renewables, Inc. Announces Approval of Provisional California Air Resource Board Carbon Intensity Score for Pico Energy Site in Idaho

MU Micron Reports Smartphone Shipments To Be Down Slightly In 2023 -Supply Growth To Lag Demand Growth In 2023

RIG: Transocean Ltd. Announces Harsh Environment Contract Awards Totaling $382 Million with Equinor, Enters into Collaboration Agreement

OXY Billionaire Warren Buffett’s company bought more than $200 million worth of Occidental Petroleum’s shares over the past week, giving it control of 23.6% of the oil producer’s stock. AP

ELOX Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

AULT: Ault Alliance’s Subsidiary, BitNile Inc., Collaborates with Core Scientific for Bitcoin Mining Expansion

CEMI: Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

REGN Libtayo(R) (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)

MTRX Enterprise Products Awards Matrix Service EPC For A Second Ethane Storage Tank Along The Texas Gulf Coast

AUVI: Applied UV Announces Strategic Financial Collaboration With Canon Financial Services

UNH UnitedHealthcare Will Remove Many Services, Devices From Prior Authorization Starting in Third Quarter – WSJ

UNG U.S. Natural Gas Flows to Freeport LNG’s Export Facility in Texas Expected to Reach 1.8 Billion Cubic Feet Per Day on Wednesday, According to Refinitiv

NNDM Nano Dimension Increases Offer to Acquire Stratasys to $19.55 Per Share in Cash

LOCL Local Bounti Secures up to $145 Million of Additional Financing to Support Growth

AFMD: Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

TFX: Teleflex Selects GORE(R) SEAMGUARD(R) Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS(R) Stapler

AULT: Ault Alliance Announces Agreement to Sell $10.0 Million Stated Value of Convertible Preferred Stock

AXNX Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas

STEM Stem proposes $175M green convertible senior notes offering

CETY: Clean Energy Technologies Enters into a Master Service Agreement with RPG Energy Group

ENVX: Enovix Announces Manufacturing Partner and Location for Fab-2 in Malaysia

GNRC DR Power Equipment Introduces Battery-Powered Brush Mower, One of the First in the Industry

DKNG DraftKings Launches DK Horse Racing App, Investing DKNG and CHDN

BA Ryanair CEO says any new Boeing order depends on price, looking at both 737 MAX 8200 and 737 MAX 10 models

MU Rosenblatt Reiterates Buy on Micron Technology, Maintains $100 Price Target

LULU PT Raised to $500 at TD Cowen

PYPD PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

CRBU: Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

EZFL SVRE: EzFill Holdings & SaverOne Launch Pilot in Florida to Prevent Driver Distraction in Fuel Delivery Trucks

FSLR Indian Government Awards Production Linked Incentives to First Solar’s India Manufacturing Facility

ACHV: Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

COCP: Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs

GOOG New Google AD tool available globally within a month.

PRQR: ProQR Announces Initial Pipeline Targets and Highlights Axiomer(R) RNA Editing Platform Technology at R&D Event

Questions or concerns about our products? Email [email protected](C) Copyright 2022, RagingBull – Refund Policy – Privacy Policy – Terms & Conditions

DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at ragingbull. com/paid-advertisement-disclaimer/.

*PAID ADVERTISEMENT. RagingBull has been paid fourteen thousand dollars by ach bank transfer by Lifewater Media for advertising RenovoRx from a period beginning on March 29, 2023 through March 30 of the same year. Previously, RagingBull has been paid ten thousand dollars by ach bank transfer by Lifewater Media for advertising RenovoRx from a period beginning on March seventh, 2023 through March eighth of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in RenovoRx. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of RenovoRx, increased trading volume, and possibly an increased share price of the RenovoRx securities, which may or may not be temporary and decrease once the marketing arrangement has ended.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at www.sec. gov/edgar/searchedgar/companysearch

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.